Loading...
Docoh

Exact Sciences (EXAS)

News

From Benzinga Pro
Why Ark Innovation ETF Hit 52-Week Lows Today
9 May 22
Movers, Trading Ideas
ARK Innovation ETF (ARCA:ARKK) is making new 52-week lows on Monday, led by sharp declines in the top holdings of Ark's flagship fund.
9 Health Care Stocks With Whale Alerts In Today's Session
6 May 22
Options
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Exact Sciences's Return On Capital Employed Insights
28 Apr 22
Earnings
According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.
Exact Sciences Highlights Updated, Expanded American Society Of Clinical Oncology Guidelines That Recommend Use Of Co.'s Oncotype Breast Recurrence Score Test
28 Apr 22
News
Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxPONDER
SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know
27 Apr 22
Analyst Ratings
SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.
Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years
27 Apr 22
Earnings, News, Dividends
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.
B of A Securities Maintains Buy on Exact Sciences, Lowers Price Target to $95
27 Apr 22
News, Price Target, Analyst Ratings
B of A Securities analyst Derik De Bruin maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $105 to $95.
Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance
27 Apr 22
Earnings, News, Guidance, Health Care, Movers, Trading Ideas, General
Raymond James Maintains Outperform on Exact Sciences, Lowers Price Target to $80
27 Apr 22
News, Price Target, Analyst Ratings
Raymond James analyst Andrew Cooper maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $90 to $80.
SVB Leerink Maintains Outperform on Exact Sciences, Lowers Price Target to $95
27 Apr 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Puneet Souda maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $130 to $95.
Exact Sciences Q1 EPS $(1.04) Beats $(1.07) Estimate, Sales $486.57M Beat $461.71M Estimate
26 Apr 22
Earnings, News
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.07) by 2.8 percent. This is a 477.78 percent decrease over losses of $(0.18) per share from the
Earnings Scheduled For April 26, 2022
26 Apr 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.
Preview: Exact Sciences's Earnings
25 Apr 22
Earnings
Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.07.
Analyst Ratings for Exact Sciences
19 Apr 22
Analyst Ratings
Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:
Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $85
19 Apr 22
News, Price Target, Analyst Ratings
Goldman Sachs maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 to $85.
Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today
6 Apr 22
Earnings, News, Dividends
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much
17 Mar 22
Earnings, News, Dividends
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.
Stocks That Hit 52-Week Lows On Tuesday
15 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday's session, 454 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
14 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 671 companies achieved new lows for the year.

Press releases

From Benzinga Pro
Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund
3 May 22
Press Releases
Catalio's Flagship Strategy Will Continue to Identify and Invest in Breakthrough Biomedical Technology Companies Founded by Serial Scientist-Entrepreneurs Catalio Capital Management, LP ("Catalio"), a leading
Exact Sciences to participate in May investor conference
2 May 22
Press Releases
MADISON, Wis., May 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conference and invited
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
28 Apr 22
Press Releases
Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxPONDER study,
Exact Sciences Announces First Quarter 2022 Results
26 Apr 22
Earnings, Press Releases
Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing revenue of $27MTotal first quarter revenue, excluding COVID-19 testing, increased 24%
Exact Sciences schedules first quarter 2022 earnings call
8 Apr 22
Press Releases
MADISON, Wis., April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 financial results after
GPO Plus (GPOX) could be a rising star in the health care industry
2 Mar 22
News, Press Releases
Inflation is back. It’s back in a major way. The consumer price index for all items rose 0.6% in January, driving up annual inflation by 7.5%. That marked the biggest gain since February 1982 and was even higher
Exact Sciences to participate in March investor conferences
28 Feb 22
Small Cap, Press Releases
MADISON, Wis., Feb. 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited
Exact Sciences Announces Fourth Quarter 2021 Results
22 Feb 22
Earnings, Press Releases
MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended